BWP
VRTX icon

Barlow Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Barlow Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
30,786
+375
+1% +$166K 1.66% 29
2026
Q1 		$13.4M Buy
30,411
+324
+1% +$151K 1.49% 27
2025
Q4 		$14M Buy
30,087
+207
+0.7% +$89.2K 1.51% 29
2025
Q3 		$12.7M Sell
29,880
-21,078
-41% -$8.81M 1.42% 30
2025
Q2 		$23.3M Buy
50,958
+865
+2% +$399K 2.79% 13
2025
Q1 		$24.7M Buy
50,093
+383
+0.8% +$178K 3.25% 8
2024
Q4 		$21.1M Buy
49,710
+2,138
+4% +$991K 2.67% 11
2024
Q3 		$21.3M Buy
47,572
+563
+1% +$270K 2.79% 9
2024
Q2 		$23.1M Buy
47,009
+796
+2% +$346K 3.19% 7
2024
Q1 		$18.3M Buy
46,213
+1,247
+3% +$527K 2.49% 11
2023
Q4 		$18.3M Buy
+44,966
New +$16.6M 2.6% 9

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Barlow Wealth Partners's VRTX Position: Q2 2026 in Review

Barlow Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, buying an estimated $166K and bringing the position to 30,786 shares worth $15.3M. The position accounts for 1.66% of the portfolio, ranked #29.

Barlow Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $24.7M in Q1 2025. 259 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Barlow Wealth Partners held 30,786 shares of Vertex Pharmaceuticals worth $15.3M as of Q2 2026.
  • Barlow Wealth Partners bought 375 Vertex Pharmaceuticals shares in Q2 2026, an estimated $166K.
  • Vertex Pharmaceuticals made up 1.66% of Barlow Wealth Partners's portfolio in Q2 2026, its #29 holding.
  • Barlow Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Barlow Wealth Partners's Vertex Pharmaceuticals position peaked at $24.7M in Q1 2025.
  • 259 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Barlow Wealth Partners's 13F filing for Q2 2026, filed 14 Jul 2026.